In this video Dr. Sarah Rutherford discusses a trial for men and women with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), who were not cured by initial treatment with R-CHOP or a similar chemotherapy.
The purpose of this study is to determine the maximum tolerated dose of selinexor when given in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) in patients with relapsed or refractory aggressive B-cell lymphomas. This is an open-label, phase 1 trial with a standard dose escalation schema.
Tumor biopsies and peripheral blood will be taken pre- and post-treatment with selinexor to examine the study’s biologic objectives.
- Men and woman greater than or equal to 18 years of age
- Confirmed diffuse large B-cell lymphoma, double/triple hit lymphoma, indolent lymphomas transformed to DLBCL or other aggressive B-cell lymphoma, and follicular lymphoma grade 3B
- Treatment with at least two cycles of one prior anthracycline-based regimen administered with curative intent
- Detailed eligiblity reviewed when you contact the study team
If you’re interested in participating in this trial please call 212-746-2919 for more information. A full listing of DLBCL trials at Weill Cornell Medicine can be found on our clinical trials listing.